Skip to content

Therapeutic Thursday: Standing Out Matters

Oyster Therapeutics has a new name and $60m to take a self-assembling brain degrader toward the clinic. Boehringer Ingelheim plans to file survodutide in obesity in 2027, but MASH could be its best shot at standing out.

A close-up of a smooth, pale pearl resting among dark, textured barnacles on a rough oyster shell.
Who's looking for one? Photo by Marin Tulard on Unsplash

Oyster Therapeutics, previously known as Kesmalea Therapeutics, has raised $60m to develop next-generation targeted protein degraders for tau-driven diseases like Alzheimer’s disease. Companies change names for all sorts of reasons. We covered Novo Nordisk’s full pivot to a new identity with its Novo rebrand. Then there are the companies trying to leave the past behind: Valeant Pharmaceuticals springs to mind.

What about a name change for creativity? We don’t see that anymore. Phoebe Buffay from the Friends sitcom had the right idea. Who wouldn’t appreciate a name like Princess Consuela Banana-Hammock?

Therapeutic Thursday is tamer, but “King Therapeutic” has a sort of charm. Rambling aside, Oyster’s name change is more on theme. The rebrand is meant to signal a new phase of development and an ambition to produce “pearls” in the form of innovative life-changing medicines. It also comes with a $60m Series A-2 led by 4BIO Capital, a London-based specialist life science venture capital fund, with participation from new investors including Eli Lilly, CE Ventures, Actium Group, and TOHO Ventures (managed by Global Brain). Existing backers Syncona, Oxford Science Enterprises (OSE), Mission BioCapital, and MGB Ventures also took part.

Targeted Protein Degradation (TPD)

TPD drugs, which include PROTACs and molecular glues, have become one of the hottest emerging areas in biopharma. They harness the cell’s natural “waste removal” machinery to target disease-causing proteins. Oyster believes it can do what many others are struggling with, and in that context, the funding makes sense.